𝔖 Bobbio Scriptorium
✦   LIBER   ✦

A two-step one-pot radiosynthesis of the potent dopamine D2/D3 agonist PET radioligand [11C]MNPA

✍ Scribed by C. Steiger; S. J. Finnema; L. Raus; M. Schou; R. Nakao; K. Suzuki; V. W. Pike; H. V. Wikström; C. Halldin


Publisher
John Wiley and Sons
Year
2009
Tongue
French
Weight
295 KB
Volume
52
Category
Article
ISSN
0022-2135

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

(R)‐(−)‐2‐[^11^C]Methoxy‐Nn‐propylnorapomorphine ([^11^C]MNPA ([^11^C]2)) is an agonist radioligand of interest for imaging D~2~/D~3~ receptors in vivo. Here we sought to develop an improved radiosynthesis of this radioligand. Reference 2 was synthesized in nine steps with an overall yield of about 5%, starting from codeine. Trimethylsilyldiazomethane proved to be a practical improvement in comparison to diazomethane in the penultimate methylation step. A protected precursor for radiolabeling ((R)‐(−)‐2‐hydroxy‐10,11‐acetonide‐Nn‐propylnoraporphine, 4) was prepared from (R)‐(−)‐2‐hydroxy‐Nn‐propylnorapomorphine (1) in 30% yield. [^11^C]2 was prepared from 4 via a two‐step one‐pot radiosynthesis. The first step, methylation of 4 with [^11^C]methyl triflate, occurred in quantitative radiochemical yield. The second step, deprotection of the catechol moiety with HCl and heat, yielded 60–90% of [^11^C]2 giving an overall incorporation yield from [^11^C]methyl triflate of 60–90%. In a typical run more than 1 GBq of [^11^C]2, was produced from carbon‐11 generated from a 10‐min proton irradiation (16 MeV; 35 µA) of nitrogen–hydrogen target gas. The radiochemical purity of [^11^C]2 was > 99% and specific radioactivity at the time of injection was 901±342 GBq/µmol (n=10). The total synthesis time was 35–38 min from the end of radionuclide production. The identity of [^11^C]2 was confirmed by comparing its LC‐MS/MS spectrum with those of reference 2 and (R)‐(−)‐10‐methoxy‐2,11‐dihydroxy‐Nn‐propylnoraporphine. Copyright © 2009 John Wiley & Sons, Ltd.


📜 SIMILAR VOLUMES


Radiosynthesis of (S)-5-methoxymethyl-3-
✍ Yann Bramoullé; Frédéric Puech; Wadad Saba; Heric Valette; Michel Bottlaender; P 📂 Article 📅 2008 🏛 John Wiley and Sons 🌐 French ⚖ 156 KB

## Abstract Within a novel series of 2‐oxazolidinones developed in the past by Sanofi‐Synthélabo, SL25.1188 ((__S__)‐5‐methoxymethyl‐3‐[6‐(4,4,4‐trifluorobutoxy)benzo[__d__]isoxazol‐3‐yl]oxazolidin‐2‐one), a compound that inhibits selectively and competitively MAO‐B in human and rat brain (Ki value